Lipotropic amino acids Methionine, Inositol, and Choline are effective in mobilizing body fat
Reported preclinical doses (for documentary purposes only) vary by route: intranasal (high bioavailability, direct BBB crossing via olfactory and trigeminal pathways), intraperitoneal, subcutaneous
P.PacherP.EvgenovO
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
In later stages, CKD leads to multiorgan failure by disrupting hormone balance, fluid-electrolyte equilibrium, toxin elimination, and blood pressure regulation
1 Introduction The global prevalence of non-alcoholic fatty liver disease (NAFLD) has shown a consistent upward trend in recent decades, with current estimates indicating an overall prevalence of 30.05% ( In a pivotal 2023 consensus statement, international liver associations proposed redefining disease terminology, replacing NAFLD with metabolic dysfunction-associated steatotic liver disease (MASLD) and NASH with metabolic dysfunction-associated steatohepatitis (MASH) ( MASLD pathogenesis involves complex interactions among multiple pathological processes, including excessive fatty acid accumulation, dysregulated inflammatory responses, oxidative stress, and insulin resistance
